

Smart Matrix Limited**MHRA approves clinical trials****Company is progressing as planned towards Q4/2018 clinical trials**

14 August 2018, Smart Matrix Limited ('SML' or 'the Company'), the advanced wound healing company, today announces that it has secured regulatory approval by the Medicines and Healthcare products Regulatory Agency (MHRA) for its planned clinical trials to commence.

The first cohort of patients will enter the trial during the fourth quarter of 2018.

For further information, please contact:

Smart Matrix Limited

Francis Gugen, Executive Chairman

gugenf@smartmatrix.co.uk, Tel: +44 (0) 7785 326 291

About Smart Matrix Limited

Smart Matrix Limited ('SML') was spun out of the Restoration of Appearance and Function Trust ("RAFT"), a medical research charity based at Mount Vernon hospital, Middlesex, UK, in late 2011.

SML is focused on the commercialisation of products from a proprietary platform technology developed by RAFT scientists based on a matrix manufactured from fibrinogen and thrombin, natural products of the healing process, and alginate, a product derived from seaweed and widely used in wound care products.

The first product developed from this platform is Smart Matrix®, a scaffold designed to help the body close surgical wounds and regenerate lost skin. Smart Matrix® works by encouraging the growth of skin cells and new blood vessels, critical to healthy healing.

SML has an exclusive, world-wide license to Smart Matrix® and first right of refusal to license other products developed by RAFT that are based on the underlying platform technology. The envisaged applications of the platform include potentially acute wound care, bone healing and regeneration, dental and soft-tissue repair.

For further information see: www.smartmatrix.co.uk